PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma

Patrizia Mondello; Stephen M. Ansell

doi:10.1016/j.ccell.2021.10.007

PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma

Patrizia Mondello, Stephen M. Ansell

Hematology

Research output: Contribution to journal › Article › peer-review

Abstract

The molecular classification of diffuse large B cell lymphoma has paved the way for precision medicine that targets oncogenic driver pathways and actionable mutations. In this issue of Cancer Cell, Wilson et al. execute a massive genomic analysis in order to identify putative molecular signatures linked to a differential response to ibrutinib plus R-CHOP.

Original language	English (US)
Pages (from-to)	1570-1572
Number of pages	3
Journal	Cancer cell
Volume	39
Issue number	12
DOIs	https://doi.org/10.1016/j.ccell.2021.10.007
State	Published - Dec 13 2021

ASJC Scopus subject areas

Oncology
Cell Biology
Cancer Research

Access to Document

10.1016/j.ccell.2021.10.007

Cite this

@article{215674bf48674c2ca20d9ec09db438e5,

title = "PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma",

abstract = "The molecular classification of diffuse large B cell lymphoma has paved the way for precision medicine that targets oncogenic driver pathways and actionable mutations. In this issue of Cancer Cell, Wilson et al. execute a massive genomic analysis in order to identify putative molecular signatures linked to a differential response to ibrutinib plus R-CHOP.",

author = "Patrizia Mondello and Ansell, {Stephen M.}",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = dec,

day = "13",

doi = "10.1016/j.ccell.2021.10.007",

language = "English (US)",

volume = "39",

pages = "1570--1572",

journal = "Cancer cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "12",

}

TY - JOUR

T1 - PHOENIX rises

T2 - Genomic-based therapies for diffuse large B cell lymphoma

AU - Mondello, Patrizia

AU - Ansell, Stephen M.

PY - 2021/12/13

Y1 - 2021/12/13

N2 - The molecular classification of diffuse large B cell lymphoma has paved the way for precision medicine that targets oncogenic driver pathways and actionable mutations. In this issue of Cancer Cell, Wilson et al. execute a massive genomic analysis in order to identify putative molecular signatures linked to a differential response to ibrutinib plus R-CHOP.

AB - The molecular classification of diffuse large B cell lymphoma has paved the way for precision medicine that targets oncogenic driver pathways and actionable mutations. In this issue of Cancer Cell, Wilson et al. execute a massive genomic analysis in order to identify putative molecular signatures linked to a differential response to ibrutinib plus R-CHOP.

UR - http://www.scopus.com/inward/record.url?scp=85120360545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120360545&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2021.10.007

DO - 10.1016/j.ccell.2021.10.007

M3 - Article

C2 - 34739842

AN - SCOPUS:85120360545

SN - 1535-6108

VL - 39

SP - 1570

EP - 1572

JO - Cancer cell

JF - Cancer cell

IS - 12

ER -

PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this